Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
2.930
-0.070 (-2.33%)
Jun 23, 2025, 4:00 PM - Market closed

Grace Therapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Grace Therapeutics stock has a target of 12, which predicts a 309.56% increase from the current stock price of 2.93.

Price Target: $12 (+309.56%)
Analyst Consensus: Strong Buy
Target Low Average Median High
Price $12 $12 $12 $12
Change +309.56% +309.56% +309.56% +309.56%
* Price targets were last updated on Feb 18, 2025.

Analyst Ratings

According to 1 stock analyst, the rating for Grace Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating May '25Jun '25
Strong Buy 11
Buy 00
Hold 00
Sell 00
Strong Sell 00
Total 11

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$12
Strong Buy Reiterates $12 +309.56% Feb 18, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
439.58K
EPS This Year
-1.01
from -0.79
EPS Next Year
-1.74
from -1.01
Fiscal Year FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2026 FY 2027
Period Ending Mar 31, 2021 Mar 31, 2022 Mar 31, 2023 Mar 31, 2024 Mar 31, 2025 Mar 31, 2026 Mar 31, 2026 Mar 31, 2027
Revenue
196.00K-----439.58K10.26M
Revenue Growth
-------2,234.05%
EPS
-7.96-1.60-5.71-1.35-0.79-1.01-1.74-0.58
EPS Growth
--------
Forward PE
--------
No. Analysts
-----644
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20262027
High 905,027 23.6M
Avg 439,579 11.6M
Low n/a 1.3M

Revenue Growth

Revenue Growth 20262027
High -
5,273.5%
Avg -
2,531.4%
Low -
203.9%

EPS Forecast

EPS 20262027
High -1.79 -0.57
Avg -1.74 -0.64
Low -1.67 -0.68

EPS Growth

EPS Growth 20262027
High - -
Avg - -
Low - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.